Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00489853
Status:
COMPLETED
Last Update Posted:
2012-08-30
First Post:
2007-06-19
Brief Title:
Evaluation of Efficacy on Exercise Tolerance of Symbicort BudesonideFormoterol Compared to Placebo and Oxis in Patients With Severe COPD
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Multi-centre Randomised Double-blind Cross-over Design Study to Evaluate Efficacy on Exercise Tolerance of Symbicort BudesonideFormoterol 3209μg One Inhalation Twice Daily Compared With Placebo and Oxis 9μg One Inhalation Twice Daily in Patients With Severe Chronic Obstructive Pulmonary Disease COPD
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CODEX
Brief Summary:
The purpose of this study is to investigate the effect on exercise tolerance lung function and symptoms after treatment with Symbicort Oxis or placebo in patients with severe chronic obstructive pulmonary disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract No 2006-006519-60 | None | None | None |